Colitis, Ulcerative Clinical Trials

15 studies are recruiting for colitis, ulcerative in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

   The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Scor…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Clinnova Research ( Site 1042), Anaheim, California

   Locations

   35 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07463183 on ClinicalTrials.gov

2. Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

   Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in …

   Stage

   Phase 3

   Ages

   Any age

   Site

   Connecticut Clinical Research Institute ( Site 0297), Bristol, Connecticut

   Locations

   37 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06651281 on ClinicalTrials.gov

3. Confirmatory Clinical Study in Active Ulcerative Colitis

   The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated. MH002 is a live bio…

   Stage

   Phase 2

   Ages

   16 and older

   Site

   ARA Professionals, Miami, Florida

   Locations

   25 in total

   Run by

   MRM Health NV

   See if you can join NCT07296315 on ClinicalTrials.gov

4. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

   Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adu…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Biopharma Informatic, LLC, Los Angeles, California

   Locations

   70 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07483073 on ClinicalTrials.gov

5. A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

   The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   BAMC, Houston, Texas

   Run by

   Janssen Scientific Affairs, LLC

   See if you can join NCT04372108 on ClinicalTrials.gov

6. A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

   The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

   Stage

   Phase 3

   Ages

   3 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   49 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06663332 on ClinicalTrials.gov

7. A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

   The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the co…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   AZ Gastro Care, Chandler, Arizona

   Locations

   401 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07196748 on ClinicalTrials.gov

8. A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

   The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinnova Research, Anaheim, California

   Locations

   170 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07577856 on ClinicalTrials.gov

9. A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

   The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07654751 on ClinicalTrials.gov

10. A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

    This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) m…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Site 024, Canoga Park, California

    Locations

    267 in total

    Run by

    Spyre Therapeutics, Inc.

    See if you can join NCT07012395 on ClinicalTrials.gov

11. A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

    The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment per…

    Stage

    Phase 2

    Ages

    2 to 11

    Site

    Fink Children's Ambulatory Care Center, New York, New York

    Locations

    42 in total

    Run by

    Pfizer

    See if you can join NCT07470879 on ClinicalTrials.gov

12. A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

    The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to c…

    Stage

    Phase 2

    Ages

    2 to 17

    Site

    Loma Linda University Health System, Loma Linda, California

    Locations

    90 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05076175 on ClinicalTrials.gov

13. An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

    The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice…

    Stage

    Not phased

    Ages

    18 to 64

    Site

    Reddy GI Associates, Mesa, Arizona

    Locations

    28 in total

    Run by

    Pfizer

    See if you can join NCT06398626 on ClinicalTrials.gov

14. Therapeutic Endpoint in Pediatric IBD Conditions

    The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory respo…

    Stage

    Not phased

    Ages

    6 to 21

    Site

    Children's National Health System, Washington D.C., District of Columbia

    Run by

    Children's National Research Institute

    See if you can join NCT06065228 on ClinicalTrials.gov

15. Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

    Approximately 20-40% of patients with ulcerative colitis (UC) are obese. The investigators have demonstrated that obesity adversely impacts disease course in patients with UC, leading to higher risk of persistently active disease, surgery, hospitalization, and treatment failure, particularly in bio…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    University of California San Diego, La Jolla, California

    Run by

    University of California, San Diego

    See if you can join NCT04721873 on ClinicalTrials.gov